Table 2.

Glycaemic control and diabetes medications at 6 months, for patients who had T2DM at baseline.

Variable (mean ± SD or %)	Baseline (n = 83)	6 months (n = 64)	P value
HbA1c (n = 76)
HbA1c (%)	7.7 ± 1.7	7.3 ± 1.3	0.003
HbA1c (mmol/mol)	61.4 ± 18.5	55.7 ± 13.7
Percentage with HbA1c < 6.5%	19.7	31.6	0.035
Number of diabetes medications per patient	1.8 ± 1.0	1.0 ± 1.2	<0.001
Type of therapy (%)
Lifestyle only	8.4	50.6	<0.001
Monotherapy	30.1	19.3	0.18
≥2 medications	61.4	30.1	<0.001
Type of medication (%)
Metformin	79.5	43.4	<0.001
Sulphonylurea	18.1	6.0	0.03
DPP-4 inhibitors	14.5	7.2	0.18
GLP-1 analogues	10.8	7.2	0.61
SGLT-2 inhibitors	26.5	14.5	0.087
Acarbose	1.0	0.0	N/A
Insulin	33.7	20.5	0.061
Insulin total daily dose (units)	138.4 ± 96.1	82.3 ± 47.5	0.014
Prescribing pattern (%)
Weight-neutral/losing	43.4	24.1	0.024
Weight-gaining	34.9	21.7	0.071
Mixed-effect	13.3	3.6	0.057